Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289867 | 0.86 | SOS1 (0.58) | SOS1HSPB1SCN4AGAALTA4H | |
| SCHEMBL636168 | 0.86 | ALDH1A1 (0.47) | GAALTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL9294674 | 0.86 | ALDH1A1 (0.47) | GAALTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL15929631 | 0.86 | ALDH1A1 (0.47) | GAALTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL6290683 | 0.86 | SOS1 (0.58) | SOS1HSPB1SCN4AGAALTA4H | |
| SCHEMBL351854 | 0.86 | SOS1 (0.58) | SOS1HSPB1SCN4AGAALTA4H | |
| SCHEMBL7367702 | 0.83 | SOS1 (0.56) | SOS1HSPB1SCN4AGAALTA4H | |
| SCHEMBL18720 | 0.83 | — | — | |
| SCHEMBL6511332 | 0.80 | — | — | |
| SCHEMBL7735437 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118380656-B | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118380656-A | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118380656-B | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118380656-A | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-1177821-C | Matrix metalloprotease inhibitors | - | 2004-12-01 | — | — | CN | disclosed |
| EP-1070069-B1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0966438-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999052910-A1 | BICYCLIC HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| CN-1232023-A | Process for preparing hydroxamic acids | PFIZER PROD INC (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998034915-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| CN-1160045-A | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 1997-09-24 | — | — | CN | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | SOS1 3762/4885HSPB1 833/4885SCN4A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.